Advanced search
Start date
Betweenand

Behavioral and electrophysiological effects of PPAR gamma agonist pioglitazone in two-hit model of schizophrenia

Grant number: 21/06775-0
Support type:Scholarships abroad - Research Internship - Post-doctor
Effective date (Start): November 01, 2021
Effective date (End): October 31, 2022
Field of knowledge:Biological Sciences - Pharmacology - Neuropsychopharmacology
Principal researcher:Leonardo Resstel Barbosa Moraes
Grantee:Andreza Buzolin Sonego
Supervisor abroad: Anthony Albert Grace
Home Institution: Faculdade de Medicina de Ribeirão Preto (FMRP). Universidade de São Paulo (USP). Ribeirão Preto , SP, Brazil
Research place: University of Pittsburgh (Pitt), United States  
Associated to the scholarship:18/20433-2 - Neuroprotective and behavioral effects of the PPAR³ agonist pioglitazone in a neurodevelopmental model of schizophrenia, BP.PD

Abstract

Schizophrenia is a complex psychiatric disorder that affects approximately 1% of the population worldwide, whose symptoms can be divided in positive, negative and cognitive. The etiology and pathophysiology of this disorder, however, are not yet completely understood, with genetic and environmental factors influencing its development. Among the environmental insults, maternal infection and stress exposure, especially during childhood and adolescence, have been implicated as risk factors for schizophrenia. Both insults induce an exacerbated inflammatory response, which could mediate disturbance of neurodevelopmental processes and, ultimately, malfunctioning of neural systems observed in schizophrenia. Thus, anti-inflammatory drugs may potentially be used to treat this disorder. Among them, the agonists of peroxisome proliferator-activated receptor gamma (PPAR³) could be explored as a therapeutic alternative. This isoform of PPAR receptors is involved in the regulation of metabolic pathways, but also presents anti-inflammatory properties. These receptors can be found in the central nervous system and their expression is reduced in patients with schizophrenia. Furthermore, some antipsychotic drugs can increase the expression of PPAR³ receptors. Therefore, the hypothesis of this study is that the PPAR³ agonist pioglitazone would attenuate the behavioral and electrophysiological alterations found in a two-hit model of schizophrenia.

News published in Agência FAPESP Newsletter about the scholarship:
Articles published in other media outlets (0 total):
More itemsLess items
VEICULO: TITULO (DATA)
VEICULO: TITULO (DATA)